Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorlatinib Continuation Study in ALK- or ROS1-positive NSCLC
jRCT2041210127Active, not recruiting
- Sponsor
- Pfizer
- Start
- Dec 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Open-label, single-arm trial of lorlatinib in ALK-positive non-small cell lung cancer and non-small cell lung cancer (NSCLC), sponsored by Pfizer. Started Dec 2021; status: active, not recruiting.
02
Drugs
lorlatinib
03
Conditions
ALK-positive non-small cell lung cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2041210127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041210127.